

Special Issue

Safety and Immunogenicity of the COVID-19 Vaccine

Message from the Guest Editor

COVID-19 vaccines were instant gamechangers when they were introduced in late 2020. Their effect on mortality and severe morbidity and, as a result, on public activities has been tremendous. On the other hand, some concerns and questions were raised regarding the safety and immunogenicity of these vaccines, both in the general population and in certain risk groups. While data continue to emerge from trials around the world, global policy-making agencies are publishing and updating guidelines and recommendations. In this Special Issue, we aim to publish the most up-to-date trials regarding the safety of or concerns around COVID-19 vaccines, regardless of the vaccine type or manufacturer, and the immunogenicity that these vaccines provide over time, in the general population as well as in special risk groups.

Guest Editor

Dr. Johad F. Khoury
Yale School of Medicine, New Haven, CT 06520-8023, USA

Deadline for manuscript submissions

closed (31 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/161709

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).